University of California at San Francisco Criteria Can Be Applied to Living Donor Liver Transplantation for Hepatocellular Carcinoma: Single-Center Preliminary Results in 27 Patients

2008 ◽  
Vol 40 (5) ◽  
pp. 1476-1480 ◽  
Author(s):  
X.-Z. Jiang ◽  
L.-N. Yan ◽  
T.-F. Wen ◽  
B. Li ◽  
Y. Zeng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
San Francisco ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
University Of California ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Preliminary Results

scholarly journals Clinical efficacy of locoregional therapy prior to living donor liver transplantation for hepatocellular carcinoma based on UCSF criteria

2019 ◽  
Author(s):  
Tsung-Han Wu ◽  
Chih-Hsien Cheng ◽  
Chen-Fang Lee ◽  
Ting-Jung Wu ◽  
Hong-Shiue Chou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
San Francisco ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Locoregional Therapy ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Regional Therapy ◽  
Ucsf Criteria

Abstract Background The study analyzed the loco-regional therapy outcomes prior to living donor liver transplantation (LDLT), to provide additional information for decision-making regarding therapeutic strategy for hepatocellular carcinoma (HCC) patients. Methods A total of 308 consecutive patients undergoing LDLTs for HCC between August 2004 and December 2018 were retrospectively analyzed. Patients subjected to loco-regional therapy prior to LT were grouped and the outcomes were compared. Results Overall, HCC recurrence after LDLT were detected in 38 patients (12.3%) during the follow-up period. By the end of the study, 205 patients, 6 of whom with recurrent HCC, were alive. Patients who had radiological imaging beyond the University of California at San Francisco (UCSF) criteria had significant inferior outcomes for both recurrence-free survival (RFS, p = 0.0005) and overall survival (OS, p = 0.0462) despite receiving loco-regional therapy as down-staging intention. Moreover, patients with profound tumor necrosis (TN) had a superior RFS at 3 and 5 years (97.4% and 93.8%, respectively), compared with others. Conclusion LDLT gains a satisfactory result based on the expanded UCSF criteria for HCC. However, the loco-regional therapy prior to LDLT does not seem to provide benefit unless a profound TN is noted.

Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience in Taiwan

2008 ◽  
Vol 85 (3) ◽  
pp. 398-406 ◽  
Author(s):  
Allan Concejero ◽  
Chao-Long Chen ◽  
Chih-Chi Wang ◽  
Shih-Ho Wang ◽  
Chih-Che Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Single Center Experience

Living Donor Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Experience of a Single Center

2017 ◽  
Vol 22 ◽  
pp. 115-120 ◽  
Author(s):  
Cheng-Chih Chang ◽  
Ying-Ju Chen ◽  
Tzu-Hao Huang ◽  
Chun-Han Chen ◽  
Fang-Ying Kuo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Living donor liver transplantation for hepatocellular carcinoma: A single-center preliminary report

2006 ◽  
Vol 12 (6) ◽  
pp. 934-940 ◽  
Author(s):  
Massimo Malagó ◽  
Georgios C. Sotiropoulos ◽  
Silvio Nadalin ◽  
Camino Valentin-Gamazo ◽  
Andreas Paul ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Preliminary Report ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Single Center ◽  
Donor Liver ◽  
Donor Liver Transplantation
Sign in / Sign up

Export Citation Format

Share Document